Enhanced Gut Microbiome Capacity for Amino Acid Metabolism is associated with Peanut Oral Immunotherapy Failure
Ozcam, M.; Lin, D. L.; Gupta, C. L.; Li, A.; Wheatley, L. M.; Baloh, C. H.; Sanda, S.; Jones, S. M.; Lynch, S. V.
Show abstract
Peanut Oral Immunotherapy (POIT) holds promise for remission of peanut allergy, though treatment is protracted and successful in only a subset of patients. Because the gut microbiome is linked to food allergy, we sought to identify fecal microbial predictors of POIT efficacy and to develop mechanistic insights into treatment response. Longitudinal functional analysis of the fecal microbiome of children (n=79) undergoing POIT in a first double-blind, placebo-controlled clinical trial, identified five microbial-derived bile acids enriched in fecal samples prior to POIT initiation that predicted treatment efficacy (AUC 0.71). Failure to induce disease remission was associated with a distinct fecal microbiome with enhanced capacity for bile acid deconjugation, amino acid metabolism, and increased peanut peptide degradation in vitro. Thus, microbiome mechanisms of POIT failure appear to include depletion of immunomodulatory secondary bile and amino acids and the antigenic peanut peptides necessary to promote peanut allergy desensitization and remission.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Postnatal intestinal epithelial maturation by LSD1 controls the small intestinal immune cell composition independently from the microbiota 96%
- Dictionary of human intestinal organoid responses to secreted niche factors at single cell resolution 96%
- Biosynthetic Enzyme-guided Disease Correlation Connects Gut Microbial Metabolites Sulfonolipids to Inflammatory Bowel Disease Involving TLR4 Signaling 96%
Similar papers in this journal
- Terminal differentiation and persistence of effector regulatory T cells essential for the prevention of intestinal inflammation 95%
- Restriction of innate Tγδ17 cell plasticity by an AP-1 regulatory axis 95%
- A longitudinal single-cell therapeutic atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease 95%
Similar papers in this journal
- Hexa-acylated lipopolysaccharides from the gut microbiota enhance cancer immunotherapy responses 97%
- Cysteine dependence in Lactobacillus iners constitutes a novel therapeutic target to modify the vaginal microbiota 97%
- A High Fraction of Oral Bacteria in the Feces Indicates Gut Microbiota Depletion with Implications for Human Health 96%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.